Lactate dehydrogenase as a biomarker for early renal damage in patients with sickle cell disease

Abstract EN

Among many complications of sickle cell disease, renal failure is the main contributor to early mortality.

It is present in up to 21% of patients with sickle cell disease.

Although screening for microalbuminuria and proteinuria is the current acceptable practice to detect and follow renal damage in patients with sickle cell disease, there is a crucial need for other, more sensitive biomarkers.

This becomes especially true knowing that those biomarkers start to appear only after more than 60% of the kidney function is lost.

The primary purpose of this study is to determine whether lactate dehydrogenase (LDH) correlates with other, direct and indirect bio-markers of renal insufficiency in patients with sickle cell disease and, therefore, could be used as a biomarker for early renal damage in patients with sickle cell disease.

Fifty-five patients with an established diagnosis of sickle cell disease were recruited to in the study.

Blood samples were taken and 24-h urine collection samples were collected.

Using Statcrunch, a data analysis tool available on the web, we studied the correlation between LDH and other biomarkers of kidney function as well as the distribution and relationship between the variables.

Regression analysis showed a significant negative correlation between serum LDH and creatinine clearance, R (correlation coefficient) = -0.44, P = 0.0008.

This correlation was more significant at younger age.

This study shows that in sickle cell patients LDH correlates with creatinine clearance and, therefore, LDH could serve as a biomarker to predict renal insufficiency in those patients.